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We applaud Firth et al.1 for addressing physical health in people with mental health problems 
and for proposing intervention and prevention targets. We were surprised, however, that the 
authors state, several times, that antipsychotics reduce mortality risk in people with psychotic 
disorders. A comprehensive review of the scientific evidence does not support this claim.  
The authors cite only two observational studies to support this claim, both co-authored by Dr. 
Tiihonen, who has multiple ties to manufacturers of antipsychotics (e.g. he was 
lecturer/speaker, consultant, and/or advisory board member for Janssen-Cilag, Eli Lilly, 
Pfizer, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb, and others; see his declaration 
here: https://academic.oup.com/schizophreniabulletin/article/41/3/656/2375074).  
Observational studies have major limitations, including inadequate control for important 
confounders, and incomplete data on mortality and drug prescriptions.2,3  
The evidence from observational studies is inconsistent. Contrary to the two favourable 
studies selectively cited by Firth et al.,1 there are epidemiologic studies suggesting that 
mortality risk is increased with antipsychotics.3  
Randomised placebo-controlled trials don’t indicate that antipsychotics reduce the mortality 
risk.4 Indeed, if meta-analysis is restricted to the elderly and dementia patients, mortality risk 
is increased relative to placebo.4  
Firth et al. are correct that there is a compelling body of evidence that antipsychotics have 
adverse cardiometabolic effects.1 A meta-analysis of randomised placebo-controlled trials 
confirms that most antipsychotics are cardiotoxic, and cause weight gain, and endocrine 
dysfunction.5 These side effects are major risk factors for death due to cardiometabolic 
disease.1  
In view of these conflicting lines of evidence it is not correct to claim that antipsychotics 
reduce the mortality risk in people with psychotic disorders and we should remain mindful of 
the possibility that they may increase this risk.  
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